Evidence-based articles on peptides, biomarkers, longevity science, and regulatory developments.
Featured Research
Seven peptides are under review at the July 23-24 PCAC meeting. Here is what the process means, which peptides are affected, and what researchers should understand before the decision.
Read ArticleSeven peptides are under review at the July 23-24 PCAC meeting. Here is what the process means, which peptides are affected, and what researchers should understand.
The 503A Bulks List governs which substances licensed compounding pharmacies can legally manufacture. Here is what researchers need to understand about the process and why the July 2026 review matters.
BPC-157 is one of the most researched peptides in the longevity space. Here is what the preclinical studies show, what researchers track, and why it appears on the July 2026 FDA review agenda.
Biomarkers are the foundation of biology-first longevity research. Here is what the key categories reveal about your biology and how they connect to longevity research protocols.
TB-500 is a synthetic analog of Thymosin Beta-4 studied for tissue repair and regenerative properties. Here is what the preclinical research shows and why it appears on the July 2026 FDA review agenda.
More research articles coming soon. Join the waitlist to be notified when new articles are published.
Join the WaitlistFor educational and research purposes only. Not medical advice. Always consult a licensed healthcare provider before making any health decisions.